Mike Visits 1 - 3: Cardiovascular risk assessment and management of a male diabetic patient with multivessel CAD and low HDL-C

1 ACPE 1 ANCC Contract Hours 1 CDR 1 AMA PRA Category 1 Credit(s)™
Launch Date:
Expiration Date:
The accreditation for this activity has expired.

Primary Audience:

No primary audience was provided.

Relevant Terms:

No primary audience was provided.

Peter P. Toth, MD, PhD, FNLA

Peter P. Toth, MD, PhD, FNLA
Director of Preventive Cardiology
Sterling Rock Falls Clinic, Ltd.
Chief of Medicine, CGH Medical Center
Sterling, Illinois
Clinical Professor
University of Illinois School of Medicine
Peoria, IL

Peter P. Toth, MD, PhD, FAAFP, FICA, FAHA, FNLA, FCCP, FACC received his B.A. in Biochemistry from Princeton University and a Ph.D. in Biochemistry from Michigan State University. He graduated from Wayne State University School of Medicine and completed residency training in Family Medicine at the University of Iowa Hospitals and Clinics.
Dr. Toth is a diplomate of the American Board of Family Practice and the American Board of Clinical Lipidology. Dr. Toth is a member of the American College of Cardiology Foundation Council on Cardiovascular Disease Prevention and the American Heart Association's Council on Lipoproteins, Lipid Metabolism, and Thrombosis.

Dr. Toth has authored and coauthored over two hundred twenty publications in medical and scientific journals and textbooks. He is Editor-in-Chief of the Year in Lipid Disorders (Atlas Publishing, Oxford, UK) and an Associate Editor for the Year Book of Endocrinology (Elsevier, New York). He is coeditor with Antonio Gotto of the textbook, Comprehensive Management of High Risk Cardiovascular Patients (Taylor and Francis, New York) with Michael Davidson of Therapeutic Lipidology (Humana, Philadelphia), with Dominic Sica of Current Controversies in Dyslipidemia Management (Atlas Publishing, Oxford), with Kevin Maki of Practical Lipid Management (Wiley-Blackstone, London), with Christopher Cannon of Comprehensive Cardiovascular Care in the Primary Care Setting (Springer Humana, Philadelphia), and Domenic Sica of Clinical Challenges in Hypertension vols I and II (Clinical Publishing, Oxford, UK). He has lectured on many topics in cardiovascular medicine throughout the world.

Robert Daniel Brook, MD

Robert Daniel Brook, MD
Associate Professor, Department of Internal Medicine
University of Michigan
Ann Arbor, MI

Dr. Brook is an associate professor of medicine in the Division of Cardiovascular Medicine at the University of Michigan (U-M). He majored in physiology at Michigan State University and graduated Phi Beta Kappa and with high honors in 1991. He attended the University of Michigan Medical School (1991-1995) and completed residency training in internal medicine at Northwestern Memorial Hospital in Chicago (1995-1998). He then returned to the University of Michigan and completed a fellowship in hypertension, hyperlipidemia, and vascular medicine 1998-99).

He then joined the University of Michigan faculty as a physician-scientist and was promoted to associate professor in 2008. Currently, Dr. Brook is a Fellow of the Society for Vascular Medicine (FSVM), a Fellow of the American Society of Hypertension (FASH), and a Fellow of the National Lipid Association (FNLA). His clinical interests are in resistant and secondary hypertension, orthostatic hypotension, complex lipid disorders, and primary cardiovascular disease prevention.

Dr. Brook has authored over 100 peer-reviewed publications in the areas of vascular biology, atherosclerosis, cardiovascular imaging, hypertension, prevention, and hyperlipidemia. However, his main research interest has been the adverse cardiovascular effects of particulate matter air pollution on humans. His emphasis has been on understanding the biological mechanisms of how air pollutants cause heart disease and/or trigger cardiovascular events, with a focus upon changes in vascular function and blood pressure. His studies have helped to foster the growth of the field, "Environmental Cardiology". These efforts culminated in him serving as the Chair and lead author on a landmark Scientific Statement by the American Heart Association regarding the cardiovascular effects of air pollution (Brook RD, et al. Circulation 2010; 121: 2331-78).

Dr. Brook has additional research interests in obesity-mediated hypertension and "alternative" non-pharmacological means to lower blood pressure. In this latter regard, he recently served as the Chair of a Scientific Statement by the American Heart Association that critically reviewed the evidence supporting the efficacy of alternative mechanisms to lower blood pressure.
1. Describe the scope of residual risk in patients with cardiovascular disease.
2. For Registered Nurses and Nurse Practitioners Only: Provide appropriate care and counsel for patients and their families